Category Archives: Cell Therapy

By David Cyranoski of Nature magazine With Texas pouring millions of dollars into developing adult stem-cell treatments, doctors there are already injecting paying customers with unproven preparations, supplied by an ambitious new company. The US Food and Drug Administration (FDA) has not approved any such stem-cell treatment for routine clinical use, although it does sanction them for patients enrolled in registered clinical trials. Some advocates of the treatments argue, however, that preparations based on a patient's own cells should not be classed as drugs, and should not therefore fall under the FDA's jurisdiction. There are certainly plenty of people eager to have the treatments. Texas governor Rick Perry, for instance, has had stem-cell injections to treat a back complaint, and has supported legislation to help create banks to store patients' harvested stem cells. One company that has benefited from this buoyant climate is Celltex Therapeutics, which "multiplies and banks" stem cells derived from people's abdominal fat, according to chairman and chief executive David Eller. Its facility in Sugar Land, just outside Houston, opened in December 2011 and houses the largest stem-cell bank in the United States. Celltex was founded by Eller and Stanley Jones, the orthopaedic surgeon who performed Perry's … Continue reading →

SILVER SPRING, Md.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, announced today Goldman Small Cap Research has reissued its buy recommendation on Nuvilex with a short term price target of $0.50 per share. According to the research report prepared by Goldman, The current share price represents but a fraction of its true value, in our view. With recently increased interest and valuation in the pancreatic cancer treatment arena, we believe that Nuvilex is worth $0.20 just on the oncology therapies alone and that the shares will reach $0.50 in the next six months. Looking ahead, as milestone events occur, $1.00 per share is within reach over the next 12-18 months. Goldman bases this value projection, in part, on the pending acquisition of SG Austria assets, and with it complete control over the cell encapsulation technology that forms the backbone of Nuvilexs planned biotechnology development. The report states in part the following: Following execution of the SG Austria asset acquisition, we expect to see a flurry of events and progress on the development side which will serve as catalysts, including when management submits its protocol for the next stage pancreatic cancer trial. We would … Continue reading →

28-02-2012 14:48 Albert Rodriguez, MD administers stem cell therapy for Hereditary Spastic Paraplegia. stemcelldrR.com, email airpainmd@aol.com See the original post: Stem Cell Therapy Procedure and Outcome - Video … Continue reading →

PORT WASHINGTON, N.Y.--(BUSINESS WIRE)-- Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, today announced it has entered into an exclusive U.S. distribution agreement with leading animal health products provider MWI Veterinary Supply Co. As part of the agreement, MWI, through its SECUROS division, will market an innovative canine platelet enhancement therapy (C-PET) kit developed by Pall to treat dogs suffering from osteoarthritis as well as tendon and ligament injuries. The disposable system provides veterinarians a quick, portable and cost-effective solution for helping dogs realize long-term relief from these painful conditions. Osteoarthritis, a major concern for owners of the more than 72 million pet dogs1 in the United States, is a chronic condition characterized by pain and stiffness in the joints. Approximately one in five adult dogs in the U.S.2 suffer from osteoarthritis. Common canine treatment methods can range from weight control and exercise to the administration of nutraceuticals and anti-inflammatory drugs. In an effort to treat the condition rather than just the symptoms, many veterinarians have begun offering alternatives like minimally-invasive cell therapy procedures. Typically offered in conjunction with some of the more traditional methods, cell therapy can help accelerate healing and lead to longer-term relief. … Continue reading →

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ:OPXA - News), a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year. 2011 highlights include: Clinical and Regulatory Granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for Tovaxin® for the treatment of patients with Secondary Progressive Multiple Sclerosis (SPMS); Published the results of the Company’s prior Phase IIb TERMS clinical trial of Tovaxin in a leading peer-reviewed publication, Multiple Sclerosis Journal; Executed strategic agreements with the American Red Cross and the Blood Group Alliance, Inc. to streamline blood procurement for future clinical trials; and Met with Health Canada’s Biologics and Genetics Therapies Directorate as part of the process to secure approval for Opexa to conduct a portion of future clinical development in Canada. Operational Optimized the manufacturing process through the implementation of a functionally closed system and single cycle cGMP process; Advanced overall clinical plans for Tovaxin and clearly defined the study protocol for the planned Phase IIb clinical trial in SPMS; Increased employee headcount thereby strengthening our overall cell therapy expertise in preparation … Continue reading →

Within each cell, mitochondria are constantly splitting in two, a process called fission, and merging back into one, called fusion. Before a cell can divide, the mitochondria must increase their numbers through fission and separate into two piles, one for each cell. By reversing an imbalance of the signals that regulate fusion and fission in rapidly dividing cancer cells, researchers were able to dramatically reduce cell division, thus preventing the rapid cell proliferation that is a hallmark of cancer growth. Increasing production of the signal that promotes mitochondrial fusion caused tumors to shrink to one-third of their original size. Treatment with a molecule that inhibits fission reduced tumor size by more than half. "We found that human lung cancer cell lines have an imbalance of signals that tilts them towards mitochondrial fission," said Stephen L. Archer, MD, the Harold Hines Jr. Professor of Medicine at the University of Chicago Medicine and senior author of the study. "By boosting the fusion signal or blocking the fission signal we were able to tip the balance the other way, reducing cancer cell growth and increasing cell death. We believe this provides a promising new approach to cancer treatment." "This could be a potential … Continue reading →

AUSTIN, Texas, Feb. 21, 2012 /PRNewswire/ -- Celling Biosciences announces a sponsorship of the 7th Annual Stem Cell Summit being held on February 21st at Bridgewaters New York in New York City. The Stem Cell Summit is consistently the premiere venue for the world's leaders in regenerative medicine to network and promote next generation technologies and cell therapies. The meeting will feature more than 30 thought leaders in stem cell therapy including Dr. Kenneth Pettine of the Orthopedic Stem Cell Institute in Loveland, Colorado.  Dr. Pettine has teamed up with Celling Biosciences' SpineSmith Division to present "Adult Stem Cell Therapy for Orthopedic and Spine Conditions Resulting from Injury or Aging."  Dr. Pettine has become an innovator in the regenerative cell therapy market and believes "regenerative therapies will become the next standard of care in treating many orthopedic conditions."  Following the Stem Cell Summit, Dr. Pettine will be presenting a discussion on regenerative therapies to the trainers and medical staff attending this year's NFL combine.  The NFL has recently gained attention from Peyton Manning going oversees to receive a cell therapy treatment for his cervical spine condition.  Dr. Pettine envisions a day when these professional athletes stop going to foreign countries to … Continue reading →

ATLANTA, GA--(Marketwire -02/21/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB - News) (OTCQB: VSTA.OB - News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has retained MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Through a network of investor-oriented online websites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital and improve shareholder value. "VistaGen's work with human stem cell technology is groundbreaking," said Sherri Snyder, Director of Marketing at MissionIR. "The company's versatile platform, Human Clinical Trials in a Test Tube™, provides clinically relevant predictions of potential heart toxicity of new drug candidates long before they are ever tested on humans. Guided by a management team with decades of experience, VistaGen's stem cell technology can potentially save billions of dollars in the healthcare industry while recapturing prior R&D investment in once-promising new drug candidates." "We are pleased to bring MissionIR on board as our external investor relations partner," said Shawn Singh, VistaGen's Chief Executive Officer. "The crucial work our company is doing can fundamentally change the way medicine is developed. Paired with MissionIR's global … Continue reading →

CAMBRIDGE, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diabetes and other diseases characterized by organ-specific cell damage, today presented preliminary data highlighting the potential of the Company's unique cell-based therapy for treating diabetes at the 7th Annual New York Stem Cell Summit. Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, provided an overview of the Company's Pathfinder Cell ("PC") technology, and presented preclinical evidence demonstrating how treatment with PCs was able to reverse the symptoms of diabetes in two different mouse models. Pathfinder Cells are a newly identified non-stem cell mammalian cell type that has the ability to stimulate regeneration of damaged tissue without being incorporated into the new tissue. In today's presentation, Dr. Franklin showed how recent experiments performed using a non-obese diabetic (NOD) mouse strain were supportive of earlier data that demonstrated complete reversal of diabetes in mice. The earlier results, which used a drug-induced diabetic mouse model, were published in Rejuvenation Research1. Though preliminary, the recent results are encouraging because the NOD mouse model is widely used and highly regarded as being predictive of human … Continue reading →

20-12-2011 08:50 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis. Link: Adult Stem Cell Treatments for COPD - Real patient results, USA Stem Cells - Marian H. Testimonial - Video … Continue reading →